What is PIRS's revenue growth forecast for 2024-2024?
(NASDAQ: PIRS) Pieris Pharmaceuticals's forecast annual revenue growth rate of -30.56% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.06%.
Pieris Pharmaceuticals's revenue in 2024 is $42,810,000.
In 2024, PIRS is forecast to generate $655,939,216 in revenue, with the lowest revenue forecast at $655,939,216 and the highest revenue forecast at $655,939,216.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.